Merck to Acquire Oncolytic Immunotherapy Developer Viralytics for $394M – Genetic Engineering & Biotechnology News
Endpoints News |
Merck to Acquire Oncolytic Immunotherapy Developer Viralytics for $394M
Genetic Engineering & Biotechnology News Merck & Co. has agreed to acquire Sydney-based Viralytics for approximately A$502 ($394 million), the companies said today, in a deal that expands the buyer’s immuno-oncology pipeline with a mid-stage oncolytic immunotherapy that has already shown … For Latest Combo, Merck Bets $394M on Viralytics, Cancer-Fighting VirusesXconomy Merck to buy Australian viral immuno-oncology firm for $394 millionReuters.com Merck to buy virus-based cancer drug firm Viralytics for $394 millionReuters Nasdaq –Seeking Alpha all 11 news articles » |
Down To Earth Magazine (press release) (blog) |
Despite huge cancer burden, India has only 0.4 million blood stem cell donors
Down To Earth Magazine (press release) (blog) Claudia Rutt—who runs one of the oldest blood stem cell donor registries in Germany, DKMS German Bone Marrow Donor Center—says that Germany’s population is more than 82 million and around seven million donors are registered. The similar is the story … |
